The FDA has since said it is reviewing its decision. Last week, Novo Nordisk (NVO) asked the FDA to have semaglutide placed on the Demonstrable Difficulties for Compounding List, arguing that ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Shares in Novo rose almost 4% after the company revised its outlook and off the back of the sales from Ozempic, which were above forecasts. The company expects 2019 sales growth of 2-5% and ...

Novo is also awaiting results from the STEP UP T2D trial, assessing semaglutide 7.2 mg in adults with type 2 diabetes and ...

Lexicon Pharmaceuticals’ pursuit of the last word in obesity candidates has attracted Novo Nordisk. The Danish drugmaker is betting $75 million in upfront and near-term milestone payments to ...

Patients are encouraged to only acquire authentic Novo Nordisk Ozempic ® (semaglutide) injection 1 mg through pharmacies and to check the product for any signs of counterfeiting before using.

Based on SOUL findings, Novo Nordisk submitted a label extension ... stroke and CV death in those treated with oral semaglutide vs placebo. The proven cardiovascular benefit reflects a profound ...

An oral, non-incretin-based obesity candidate, LX9851 is different from Novo's (NVO) blockbuster weight loss therapy semaglutide, which is designed to target a gut hormone (incretin) known as GLP-1.

PLAINSBORO, N.J., April 14, 2025 /PRNewswire/ -- Novo Nordisk has become aware of several hundred units of Ozempic ® (semaglutide) injection 1 mg distributed outside the Novo Nordisk authorized ...

Bagsværd, Denmark, 29 March 2025 – Novo Nordisk today presented the full results from the SOUL cardiovascular outcomes trial, demonstrating that Rybelsus ® (oral semaglutide) significantly ...